Allogene Therapeutics Inc (NASDAQ:ALLO) Expected to Post Earnings of -$0.47 Per Share

Wall Street analysts expect that Allogene Therapeutics Inc (NASDAQ:ALLO) will announce earnings per share (EPS) of ($0.47) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Allogene Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.54) and the highest estimate coming in at ($0.37). The business is scheduled to report its next quarterly earnings report on Tuesday, August 6th.

On average, analysts expect that Allogene Therapeutics will report full-year earnings of ($1.94) per share for the current year, with EPS estimates ranging from ($2.10) to ($1.45). For the next financial year, analysts forecast that the company will post earnings of ($2.37) per share, with EPS estimates ranging from ($2.89) to ($1.71). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow Allogene Therapeutics.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08.

Several brokerages recently issued reports on ALLO. Zacks Investment Research upgraded Gerdau from a “sell” rating to a “hold” rating in a research note on Monday, May 13th. Guggenheim reiterated a “hold” rating on shares of Burlington Stores in a research note on Thursday, May 30th. Stifel Nicolaus set a $154.00 target price on argenx and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Roth Capital began coverage on Allogene Therapeutics in a research note on Wednesday, June 5th. They set a “neutral” rating and a $26.00 target price for the company. Finally, Oppenheimer began coverage on Allogene Therapeutics in a research note on Friday, May 3rd. They set an “outperform” rating and a $45.00 target price for the company. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $35.44.

NASDAQ ALLO traded down $0.21 during trading on Friday, reaching $26.40. 320,634 shares of the company’s stock were exchanged, compared to its average volume of 517,616. The firm’s 50 day simple moving average is $26.99. The firm has a market capitalization of $3.23 billion and a PE ratio of -4.01. The company has a quick ratio of 17.48, a current ratio of 17.48 and a debt-to-equity ratio of 0.05. Allogene Therapeutics has a fifty-two week low of $21.67 and a fifty-two week high of $35.55.

In other news, insider Alison Moore sold 48,828 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $26.76, for a total transaction of $1,306,637.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Group Holdings (Sbs) Advis Tpg sold 1,918,755 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $29.38, for a total transaction of $56,373,021.90. The disclosure for this sale can be found here. 36.50% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in ALLO. Rhumbline Advisers acquired a new position in Allogene Therapeutics during the 4th quarter worth $829,000. First Trust Advisors LP acquired a new position in Allogene Therapeutics during the 4th quarter worth $2,732,000. BlackRock Inc. acquired a new position in Allogene Therapeutics during the 4th quarter worth $56,011,000. Bank of New York Mellon Corp acquired a new position in Allogene Therapeutics during the 4th quarter worth $941,000. Finally, Raymond James & Associates acquired a new position in Allogene Therapeutics during the 4th quarter worth $673,000. Institutional investors own 53.47% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Featured Story: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Allogene Therapeutics (ALLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.